Identification of a small molecule that simultaneously suppresses virulence and antibiotic resistance of Pseudomonas aeruginosa

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guo, Qiaoyun ^a   Wei, Yu ^a   Xia, Bin ^a   Jin, Yongxin ^a   Liu, Chang ^a   Pan, Xiaolei ^a   Shi, Jing ^a   Zhu, Feng ^a   Li, Jinlong ^a   Qian, Lei ^a   Liu, Xinqi ^a   Cheng, Zhihui ^a   Jin, Shouguang ^a,b   Lin, Jianping ^a   Wu, Weihui ^a  

^a NANKAI UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OROTIC ACID; PYOCYANINE; TYPE III SECRETION SYSTEM; URACIL; VIRULENCE FACTOR;

ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BIOFILM; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORTALITY; MOUSE; MUTATION; PATHOGENICITY; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TYPE III SECRETION SYSTEM; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; GENES, BACTERIAL; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; OROTIC ACID; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYOCYANINE; TYPE III SECRETION SYSTEMS; URACIL; VIRULENCE; VIRULENCE FACTORS;

EID: 84954145932     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19141     Document Type: Article

References (66)

1. Jones, R. N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119, 397S-404S (2001).
2. Williams, J. β -lactamases and β -lactamase inhibitors. Int J Antimicrob Agents 12, S3-S7 (1999).
3. Duncan, M. C., Linington, R. G. & Auerbuch, V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother 56, 5433-5441 (2012).
4. Imperi, F. et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc Natl Acad Sci USA 110, 7458-7463 (2013).
5. Lyne, P. D. Structure-based virtual screening: an overview. Drug discov today 7, 1047-1055 (2002).
6. Jorgensen, W. L. et al. Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. ACS Med Chem Lett 16, 663-667 (2006).
7. Kime, L. et al. The first small-molecule inhibitors of members of the ribonuclease E family. Sci Rep 5, (2015).
8. Lyczak, J. B., Cannon, C. L. & Pier, G. B. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2, 1051-1060 (2000).
9. Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7, 654-665 (2009).
10. Mulcahy, H. et al. Pseudomonas aeruginosa RsmA plays an important role during murine infection by influencing colonization, virulence, persistence, and pulmonary inflammation. Infect Immun 76, 632-638 (2008).
11. Takase, H., Nitanai, H., Hoshino, K. & Otani, T. Impact of Siderophore Production on Pseudomonas aeruginosa Infections in Immunosuppressed Mice. Infect Immun 68, 1834-1839 (2000).
12. Dötsch, A. et al. Genomewide identification of genetic determinants of antimicrobial drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53, 2522-2531 (2009).
13. Lister, P. D., Wolter, D. J. & Hanson, N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22, 582-610 (2009).
14. Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Microbiol Rev 34, 634-640 (2002).
15. Høiby, N., Frederiksen, B. & Pressler, T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4, 49-54 (2005).
16. Lyczak, J. B., Cannon, C. L. & Pier, G. B. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15, 194-222 (2002).
17. Hentzer, M. & Givskov, M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Invest 112, 1300 (2003).
18. Smith, P. A. & Romesberg, F. E. Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. Nat Chem Biol 3, 549-556 (2007).
19. Liberati, N. T. et al. An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad Sci 103, 2833-2838 (2006).
20. Alvarez-Ortega, C., Wiegand. I., Olivares, J., Hancock, R. E. & Martínez, J. L. Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to β - lactam antibiotics. Antimicrob Agents Chemother 54, 4159-4167 (2010).
21. Breidenstein, E. B., Khaira, B. K., Wiegand, I., Overhage, J. & Hancock, R. E. Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrob Agents Chemother 52, 4486-4491 (2008).
22. Siryaporn, A., Kuchma, S. L., O'Toole, G. A. & Gitai, Z. Surface attachment induces Pseudomonas aeruginosa virulence. Proc Natl Acad Sci 111, 16860-16865 (2014).
23. Feinbaum, R. L., et al. Genome-wide identification of Pseudomonas aeruginosa virulence-related genes using a Caenorhabditis elegans infection model. PLoS Pathog 8, e1002813 (2012).
24. Lau, G. W., Hassett, D. J., Ran, H. & Kong, F. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol Med 10, 599-606 (2004).
25. Nørager, S., Jensen, K. F., Björnberg, O. & Larsen, S. E. coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure 10, 1211-1223 (2002).
26. Howell, H. A., Logan, L. K. & Hauser, A. R. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 4, e00032-00013 (2013).
27. Dacheux, D., Attree, I. & Toussaint, B. Expression of ExsA in trans confers type III secretion system-dependent cytotoxicity on noncytotoxic Pseudomonas aeruginosa cystic fibrosis isolates. Infect Immun 69, 538-542 (2001).
28. Aendekerk, S. et al. The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication. Microbiology 151, 1113-1125 (2005).
29. Sekiya, H. et al. Functional cloning and characterization of a multidrug efflux pump, mexHI-opmD, from a Pseudomonas aeruginosa mutant. Antimicrob Agents Chemother 47, 2990-2992 (2003).
30. Cornelis, P., Matthijs, S. & Van Oeffelen, L. Iron uptake regulation in Pseudomonas aeruginosa. Biometals 22, 15-22 (2009).
31. Llamas, M. A. et al. The heterologous siderophores ferrioxamine B and ferrichrome activate signaling pathways in Pseudomonas aeruginosa. J Bacteriol 188, 1882-1891 (2006).
32. Brichta, D. M., Azad, K. N., Ralli, P. & O'Donovan, G. A. Pseudomonas aeruginosa dihydroorotases: a tale of three pyrCs. Arch Microbiol 182, 7-17 (2004).
33. Erickson, J. A., Jalaie, M., Robertson, D. H., Lewis, R. A. & Vieth, M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem 47, 45-55 (2004).
34. Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47, 1739-1749 (2004).
35. Copeland, R. A. et al. Recombinant human dihydroorotate dehydrogenase: expression, purification, and characterization of a catalytically functional truncated enzyme. Arch Biochem Biophys 323, 79-86 (1995).
36. Marcinkeviciene, J. et al. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem Pharmacol 60, 339-342 (2000).
37. Copeland, R. A. et al. Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis. J Biol Chem 275, 33373-33378 (2000).
38. Yeung, A. T., Bains, M. & Hancock, R. E. The sensor kinase CbrA is a global regulator that modulates metabolism, virulence, and antibiotic resistance in Pseudomonas aeruginosa. J Bacteriol 193, 918-931 (2011).
39. Clatworthy, A. E., Pierson, E. & Hung, D. T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3, 541-548 (2007).
40. Palmer, A. C. & Kishony, R. Opposing effects of target overexpression reveal drug mechanisms. Nature communications 5, 4296 (2014).
41. Wang, J-L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci 97, 7124-7129 (2000).
42. Driscoll, J. A., Brody, S. L. & Kollef, M. H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67, 351-368 (2007).
43. Coggan, K. A. & Wolfgang, M. C. Global regulatory pathways and cross-talk control Pseudomonas aeruginosa environmental lifestyle and virulence phenotype. Curr Issues Mol Biol 14, 47 (2012).
44. Chua, S. L. et al. Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles. Nat Commun 5, 4462 (2014).
45. Rietsch, A., Wolfgang, M. C. & Mekalanos, J. J. Effect of metabolic imbalance on expression of type III secretion genes in Pseudomonas aeruginosa. Infect Immun 72, 1383-1390 (2004).
46. Garavaglia, M., Rossi, E., Landini, P. & Marinus, M. G. The pyrimidine nucleotide biosynthetic pathway modulates production of biofilm determinants in Escherichia coli. PLoS One 7, e31252 (2012).
47. Ueda, A., Attila, C., Whiteley, M. & Wood, T. K. Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist. Trends Biotechnol 2, 62-74 (2009).
48. Wu, W. & Jin, S. PtrB of Pseudomonas aeruginosa suppresses the type III secretion system under the stress of DNA damage. J Bacteriol 187, 6058-6068 (2005).
49. Aiello, D. et al. Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother 54, 1988-1999 (2010).
50. Li, Y., Huang, W., Huang, S., Du, J. & Huang, C. Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem Biophys Res Commun 422, 85-90 (2012).
51. O'Toole, G. A. & Kolter, R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol microbiol 30, 295-304 (1998).
52. Neidig, A. et al. TypA is involved in virulence, antimicrobial resistance and biofilm formation in Pseudomonas aeruginosa. BMC Microbiol 13, 77 (2013).
53. Temmerman, W. et al. Leafy Gall Formation Is Controlled byfasR, an AraC-Type Regulatory Gene in Rhodococcus fascians. J Bacteriol 182, 5832-5840 (2000).
54. Philippon, L. N., Naas, T., Bouthors, A-T., Barakett, V. & Nordmann, P. OXA-18, a class D clavulanic acid-inhibited extendedspectrum beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 41, 2188-2195 (1997).
55. Essar, D., Eberly, L., Hadero, A. & Crawford, I. Identification and characterization of genes for a second anthranilate synthase in Pseudomonas aeruginosa: interchangeability of the two anthranilate synthases and evolutionary implications. J Bacteriol 172, 884-900 (1990).
56. Sui, SJ. H. et al. Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. Int J Antimicrob Agent 40, 246-251 (2012).
57. Wu, W. et al. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 186, 420-427 (2012).
58. Takashima, E. et al. Characterization of the dihydroorotate dehydrogenase as a soluble fumarate reductase in Trypanosoma cruzi. Mol Biochem Parasitol 122, 189-200 (2002).
59. Samal, H. B., Das, J. K., Mahapatra, R. K. & Suar, M. Molecular modeling, simulation and virtual screening of MurD ligase protein from Salmonella typhimurium LT2. J Pharmacol Toxicol Methods 73, 34-41 (2015).
60. Lins, L. et al. The Human VPAC1 Receptor THREE-DIMENSIONAL MODEL AND MUTAGENESIS OF THE N-TERMINAL DOMAIN. J Biol Chem 276, 10153-10160 (2001).
61. Huang, B. MetaPocket: a meta approach to improve protein ligand binding site prediction. OMICS 13, 325-330 (2009).
62. Pearlman, D. A. et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 91, 1-41 (1995).
63. Cornell, W. D. et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117, 5179-5197 (1995).
64. Wang, J., Cieplak, P. & Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J Comput Chem 21, 1049-1074 (2000).
65. Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47, 1750-1759 (2004).
66. Björnberg, O., Grüner, A-C., Roepstorff, P. & Jensen, K. F. The activity of Escherichia coli dihydroorotate dehydrogenase is dependent on a conserved loop identified by sequence homology, mutagenesis, and limited proteolysis. Biochemistry 38, 2899-2908 (1999).